Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine
Burton J. Tabaac, Kenneth Shinozuka, Anne Weisman, Shiven Chaudhry, Mathieu Seynaeve, Owen S. Muir
American Journal of Therapeutics February 20, 2026 DOI: 10.1097/mjt.0000000000002106 via OpenAlex
Summary
AI-generated from the abstract5-MeO-DMT, an ultra-short-acting psychedelic, shows promise for treating depression that does not respond to other therapies, as well as other psychiatric conditions. This evidence supports the need for larger randomized controlled trials to further investigate its effectiveness.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Population | Treatment-resistant depression and other psychiatric conditions |
| Keywords | Primary care Primer cosmetics Depression economics Medline Primary health care |
| Key finding | Emerging evidence supports 5-MeO-DMT as a promising treatment for treatment-resistant depression and other psychiatric conditions, warranting larger RCTs. |
Abstract
Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric conditions, warranting larger RCTs.